A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo Mgodi, Simbarashe Takuva, Srilatha Edupuganti et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 45
Virologic outcomes in early antiretroviral treatment: HPTN 052Susan H. Eshleman, Jessica M. Fogel, Theresa Gamble et al.|HIV Clinical Trials|2017Cited by 33
1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected IndividualsSrilatha Edupuganti, Lawrence Corey, Nyaradzo Mgodi et al.|Open Forum Infectious Diseases|2019Cited by 0
Virologic outcomes in early antiretroviral treatment: HPTN 052Susan H. Eshleman, Jessica M. Fogel, Ethan Wilson et al.|Figshare|2017Cited by 0